Biosimilar Approval Is New Focus In Senate Critique Of FDA Guidance Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg describes a Catch-22, warning that pressure to finalize guidances faster without more resources could result in fewer discretionary guidances, disappointing stakeholders.
You may also be interested in...
Pfizer Says FDA Draft Guidance Is Just Fine; Congress Should Be Patient
In an unusual move, industry rep indicates comfort with draft guidance implementing biosimilar pathway.
FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.